

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lanfear Dennis M</u>  (Last) (First) (Middle) COHERUS BIOSCIENCES, INC. 201 REDWOOD SHORES PARKWAY, SUITE 200  (Street) REDWOOD CA 94065 CITY  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/06/2014	3. Issuer Name and Ticker or Trading Symbol <u>Coherus BioSciences, Inc. [ CHRS ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below)  See Remarks	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, \$0.0001 par value	50,989	D	
Common Stock, \$0.0001 par value	1,358,728	I	By Revocable Trust <sup>(1)</sup>

## Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series B Preferred Stock	(2)	(3)	Common Stock 14,509	0.00	D	
Series B Preferred Stock	(2)	(3)	Common Stock 3,193	0.00	I	By Revocable Trust <sup>(1)</sup>
Series A Preferred Stock	(2)	(3)	Common Stock 40,159	0.00	I	By LLC <sup>(4)</sup>
Series B Preferred Stock	(2)	(3)	Common Stock 21,527	0.00	I	By LLC <sup>(4)</sup>
Series C Preferred Stock	(2)	(3)	Common Stock 5,286	0.00	I	By LLC <sup>(4)</sup>
Warrant to Purchase Series A Preferred Stock	(5)	01/26/2016	Series A Preferred Stock 19,976	1.2503	I	By LLC <sup>(4)</sup>
Warrant to Purchase Series B Preferred Stock	(5)	07/21/2018	Series B Preferred Stock 3,225	0.0167	D	
Stock Option (Right to Buy)	(6)	10/11/2020	Common Stock 29,994	0.0083	D	
Stock Option (Right to Buy)	(7)	07/17/2021	Common Stock 331,054	0.4168	D	
Stock Option (Right to Buy)	(8)	11/21/2023	Common Stock 299,940	1.417	D	
Stock Option (Right to Buy)	(9)	03/10/2024	Common Stock 480,739	1.667	D	
Stock Option (Right to Buy)	(9)	03/10/2024	Common Stock 418,638	1.667	D	

## Explanation of Responses:

- These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
- The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically convert into shares of Issuer's Common Stock on a 1:1 basis immediately prior to the completion of Issuer's initial public offering.
- The expiration date is not relevant to the conversion of these securities.
- These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
- The warrant is immediately exercisable.
- The shares underlying this option are fully vested and exercisable as of the date hereof.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from April 19, 2011 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from July 20, 2013, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from March 11, 2014, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

**Remarks:**

President and Chief Executive Officer

/s/ Matthew R. Hooper, as  
Attorney-in-Fact for Dennis M. Lanfear 11/06/2014

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of (i) the Chief Financial Officer of Coherus BioSciences, Inc., a Delaware corporation (the "Company"), who is currently Jean-Frederic Viret, Ph.D., (ii) the Company's Senior Vice President, Legal Affairs and General Counsel, who is currently Matthew R. Hooper and (iii) the Company's Controller, who is currently Guy Shields, and their respective successors, signing singly, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer or director of the Company, Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 or Form ID and timely file such forms (including amendments thereto) and application with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

The undersigned agrees that each such attorney-in-fact herein may rely entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based upon any untrue statements or omission of necessary facts in the information provided by the undersigned to such attorney-in fact for purposes of executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including amendments thereto) or Form ID and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney supersedes any power of attorney previously executed by the undersigned regarding the purposes outlined in the first paragraph hereof ("Prior Powers of Attorney"), and the authority of the attorneys-in-fact named in any Prior Powers of Attorney is hereby revoked.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined in the first paragraph hereof dated as of a later date.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of October, 2014.

/s/ Dennis M. Lanfear

-----  
DENNIS M. LANFEAR